Drug Trial Radar · NCT02866825
Studying Complement Inhibition in Complex Cardiac Surgery
Last checked: Nov 19, 2026Latest source record: Feb 15, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
116
Actual
Start
May 2016
Primary completion
Dec 2016
Study completion Jan 2017
Sponsor
- Lead sponsor
- InflaRx GmbHIndustry
- Sponsor type
- Industry
- First posted
- Aug 15, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial enrolls patients undergoing a complex cardiac surgery. The primary goal of the trial is to evaluate the pharmacodynamic dose response relationship of the monoclonal antibody IFX-1 in these patients. In addition, this trial further aims to characterize the safety and the pharmacokinetics of IFX-1 as well as to collect first data on its efficacy on clinical surrogate endpoints.
Conditions
- Systemic Inflammatory Response Syndrome
- C.Surgical Procedure; Cardiac
Interventions
IFX-1Biological
PlaceboBiological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Peak level of IL-6Time frame: From prior study drug administration until 24h after start of cardiopulmonary bypass (CPB) (CPB)
Locations
10 sites in 1 country. Site status is shown where the registry gives one.
Study Site
Aachen, Germany
Study Site
Dortmund, Germany
Study Site
Dresden, Germany
Study Site
Freiburg im Breisgau, Germany
Study Site
Heidelberg, Germany
Study Site
Jena, Germany
Study Site
Kiel, Germany
Study Site
Leipzig, Germany
Study Site
Trier, Germany
Study Site
Tübingen, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.